News
MIG USA, a North Carolina Company, to Bring Needed Relief Through the Provision of Coronavirus Test Kits
MIG USA, LLC , a High Point, North Carolina company having focus in the biotechnology, pharmaceutical, and clinical research sectors, along with its corporate...
Press Releases
FDA Provides Emergency Use Authorization to PerkinElmer for COVID-19 Testing
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, announced that the U.S. FDA has provided Emergency Use Authorization (EUA) for...
Press Releases
Vir Biotechnology Proceeding with Two Clinical Development Candidates for COVID-19
Vir Biotechnology, Inc announced that it has identified multiple human monoclonal antibody (mAb) development candidates that neutralize SARS-CoV-2, the virus responsible for COVID-19.
“We are...
Press Releases
Positive update on the development of new XF-platform drug formulations
Destiny Pharma , a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global challenge of...
News
Pfizer Wins New Pediatric Approval for Atopic Dermatitis Ointment Eucrisa
The U.S. FDA greenlit a new pediatric approval for Pfizer’s Eucrisa ointment in the treatment of mild-to-moderate atopic dermatitis, an inflammatory skin disease that...
Press Releases
AbbVie announces positive topline results from phase 3 trial of VENCLEXTA, Azacitidine combo in AML
AbbVie announced the VIALE-A (M15-656) trial of Venetoclax in combination with azacitidine versus azacitidine in combination with placebo met its dual primary endpoints of...
News
OliX Pharmaceuticals Advances RNAi Approaches to Target Highly Conserved Regions of Coronavirus RNAs
OliX Pharmaceuticals, Inc. , a leading developer of RNA interference (RNAi), announced that it will leverage previous preclinical research for developing siRNA therapeutics in...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read